GLP-1 drugsHuman trial
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial
Lancet
The paper
Klara R Klein, Carol Wysham, Katherine R Tuttle, Eric R Meskimen
Show 7 more authors
Melanie Jane Davies, David Cox, Jiaxun Chen, Wen-Shuo Wu, Max Denning, Rong Liu, Lisa Ludwig,University of North Carolina at Chapel Hill · Eli Lilly (United States)
Lancet · 30 Sep 2026